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Abstract Vitamin D is an important determinant of bone
health at all ages. The plasma concentrations of 25-hydroxy
vitamin D (25-OH D) and other metabolites are used as
biomarkers for vitamin sufficiency and function. To allow
for the simultaneous determination of five vitamin D
metabolites, 25-OH D3, 25-OH D2, 24,25-(OH)2 D3, 1,25-
(OH)2 D3, and 1,25-(OH)2 D2, in low volumes of human
plasma, an assay using ultra-high-performance liquid
chromatography–tandem mass spectrometry (UHPLC-MS/
MS) was established. Plasma samples were spiked with
isotope-labeled internal standards and pretreated using
protein precipitation, solid-phase extraction (SPE) and a
Diels–Alder derivatization step with 4-phenyl-1,2,4-
triazoline-3,5-dione. The SPE recovery rates ranged from
55% to 85%, depending on the vitamin D metabolite; the
total sample run time was <5 min. Mass spectrometry
was conducted using positive ion electrospray ionization
in the multiple reaction monitoring mode on a quadrupole–
quadrupole-linear ion trap instrument after pre-column
addition of methylamine to increase the ionization
efficiency. The intra- and inter-day relative standard
deviations were 1.6–4.1% and 3.7–6.8%, respectively. The
limit of quantitation for these compounds was deter-
mined to be between 10 and 20 pg/mL. The 25-OH D
results were compared with values obtained for reference
materials (DEQAS). In addition, plasma samples were
analyzed with two additional Diasorin antibody assays.
All comparisons with conventional methods showed
excellent correlations (r
2=0.9738) for DEQAS samples,
demonstrating the high degree of comparability of the new
UHPLC-MS/MS technique to existing methods.
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Introduction
Vitamin D plays a pivotal role in calcium homeostasis and
skeletal metabolism throughout life [1]. Vitamin D is also
important for the functioning of many other systems, such
as the immune, cardiovascular, and reproductive systems
[2, 3]. Vitamin D appears in two forms: the naturally
occurring vitamin D3 in mammals and vitamin D2 derived
from plant sources and chemical synthesis. The synthetic
D2 forms offer the potential to be used as a tracer for
investigating vitamin D metabolism. Vitamin D is hydrox-
ylated in the liver to 25-hydroxyvitamin D (25-OH D) and
released in the circulation, where it circulates mostly bound
to vitamin D binding protein (DBP). The plasma concen-
tration of 25-OH D is the most commonly used biomarker
for vitamin D status and serves as a reservoir for further
hydroxylation in the kidney and extra-renal tissues to
1α,25-dihydroxy-vitamin D (1,25-(OH)2 D) or 24,25-
dihydroxy-vitamin D (24,25-(OH)2 D) [4]. 1,25-(OH)2 D
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the circulation bound to DBP. The 1,25-(OH)2 D metabolite
is considered to be most biologically active form whereas
24,25-(OH)2 is generally thought to be the first step in the
metabolic pathway of D 25-OH D [4–6]. The plasma
concentration of 24,25-(OH)2 D, its ratio to other metabo-
lites, and the rate of turnover of 25-OH D have been
proposed to have potential as alternative markers of vitamin
D status [1].
Measurement of vitamin D metabolites in plasma is
challenging because they are lipophilic, they are tightly
bound to DBP, and their plasma concentrations are very
low, in the namomolar range for 25-OH D3 and 25-OH D3
and picomolar levels for 1,25-(OH)2 D3 [7]. In addition,
quantitation of vitamin D metabolites has proven difficult
due to anomalous behavior of exogenously spiked metab-
olites, particularly in immunoassays [8], limiting the
possibilities for correction of recovery and international
standardization of assays. Immunoassays for 25-OH D and
1,25-(OH)2 D measure total metabolite concentration
because they cannot distinguish between the D2 and D3
forms [9]. In addition, immunoassays for 25-OH D cross-
react with 24,25-(OH)2 D3 [10].
Liquid chromatography (LC) with ultraviolet detection
was, until recently, regarded as the standard technique
for quantifying vitamin D [11–13]. Unfortunately, the
limits of detection (LOD) and the required sample
amounts are too high for application to circulating vitamin
D metabolites present at very low concentration levels. Gas
chromatography (GC)–mass spectrometry has also been
applied to vitamin D metabolite quantitation [14, 15];
however, the high temperatures used in GC analyses often
result in the formation of pyro and isopyro isomers of the
metabolites and there is a risk of metabolite degradation.
This can be avoided by using LC-MS/MS based methods
[16]. LC-MS methods allow the separation of compounds
based on their polarities, ionization behaviors, and mass-
to-charge (m/z) ratios and can offer very low limits of
quantitation. LC-MS methods have been successfully used
for the detection of vitamin D metabolites in conjunction
with fast atom bombardment [16], thermospray [17],
and atmospheric-pressure ionization techniques such as
electrospray ionization (ESI) and atmospheric-pressure
chemical ionization [18–34]. In addition, pre- and post-
column derivatization has been used to the enhance ionization
efficiencies of vitamin D compounds. Cookson-type
triazolinediones and triazolinediones-related reagents (e.g.,
4-phenyl-1,2,4-triazoline-3,5-dione (PTAD)) have been
used as dienophiles to react with the cisoid diene moiety
[35–40]. A further increase of the ionization efficiency of
25-OH D was achieved by adding methylamine to the
mobile phase, after PTAD derivatization, as reported by
Higashi et al. [41]. However, these techniques lacked the
sensitivity required to detect the low abundant vitamin D
metabolites such as 1,25-(OH)2 D3 and others. In this
paper, we describe a sensitive assay using UHPLC-MS/
MS after PTAD derivatization for the quantitative deter-
mination of 25-OH D3,2 5 - O HD 2, 24,25-(OH)2 D3,1 , 2 5 -
(OH)2 D3, and 1,25-(OH)2 D2 in human plasma. Different
methods for sample pretreatment and chromatography
parameters were tested to improve recovery and detection
sensitivity.
Experimental
Materials
Standards of 25-OH D3, 25-OH D2, 24,25-(OH)2 D3, 1,25-
(OH)2 D3, 1,25-(OH)2D2, and PTAD were purchased from
Sigma-Aldrich (Gillingham, UK). Stable isotope-labeled
D6-25-OH D3, D6-25-OH D2, D6-1,25-(OH)2 D3, and
D6-1,25-(OH)2 D2 (containing six deuterium atoms, three
at C-26 and three at C-27) were synthesized by Chemaphor
Inc. (Ottawa, ON, Canada). The HPLC-grade solvents
methanol, acetonitrile, ethyl acetate, formic acid, and acetic
acid were bought from Fisher Chemicals (Loughborough,
UK). Oasis HLB solid-phase extraction (SPE) syringe
barrel cartridges (1 mL, 30 mg sorbent) and Oasis HLB
μelution SPE plates were purchased from Waters (Elstree,
UK). Water was purified with a Barnsted Nanopure
Diamond System (Barnsted International, Dubuque, IA,
USA). Water and solvents used for the mobile phases were
filtered with a 0.2-μm Supelco Nylon 66 membrane
(Supelco, Bellefonte, PA, USA). Oxygen-free nitrogen and
zero air were generated with an AB5000TGS gas generator
(Parker Dominick Hunter, Tyne & Wear, UK).
Preparation of standard solutions and biological samples
Standards were dissolved in acetonitrile and deuterated
standards in methanol to obtain 0.5 mg/mL stock solutions
and stored at −20 °C. Working solutions were made by
serial acetonitrile dilutions of the stock solutions. Plasma
samples for method development were obtained from
healthy volunteers and pooled to ensure anonymity. Ethical
approval was obtained from Cambridge LREC 05/Q0108/
30. Cross-calibration with Diasorin methods was performed
using plasma samples from subjects included in earlier
studies as detailed below [42, 43]. Plasma samples (200 or
50 μL) were spiked with 20 or 5 μL respectively of
deuterated vitamin D standards, for SPE and liquid–liquid
extraction (LLE) or μelution SPE respectively as internal
standards, and incubated at room temperature for 1 h.
Different methods and conditions for sample pretreat-
ment, extraction, and derivatization were tested to optimize
780 S. Ding et al.recovery and signal-to-noise ratio as illustrated in Fig. 1
and further described in the “Results and discussion”
section. Optimum results were obtained using the sample
pretreatment extraction methods described below and was
used for all subsequent analyses.
Sample pretreatment
To precipitate protein and dissociate vitamin D metabolites
from vitamin D binding proteins, acetonitrile (500 μL for
SPE and LLE, 150 μL for μelution SPE) was added and
vortexed for 1 min, and proteins were spun down by
centrifugation for 15 min at 10,000×g. The supernatant was
transferred to an Eppendorf vial, and acetonitrile was
removed by using a gentle flow of nitrogen. The remaining
solution was subjected to further sample preparation and
SPE, LLE, or μelution SPE.
Solid-phase extraction and μelution SPE
For the SPE experiments, 800 μL of deionized water was
added to the samples after protein precipitation and
vortexed. For μelution SPE, 200 μL was used. The SPE
cartridges were first activated with ethyl acetate, followed
by methanol and equilibration with water (for SPE, 1 mL
and for μelution SPE, 200 μL of each were used). The
samples were then loaded onto the SPE cartridges or
μelution plates and extracted using gravity or negative
pressure, respectively. Cartridges were subsequently
washed with 1 mL of H2O and 1 mL of aqueous 30%
methanol, followed by drying using negative pressure.
Samples were eluted first with 1 mL or 200 μLo f
acetonitrile, followed by 0.5 mL or 50 μLo fe t h y l
acetate into Eppendorfs vials for SPE or μelution SPE,
respectively.
Liquid–liquid extraction
For LLE, 200 μL ethyl acetate and 100 μLw a t e rw e r e
added to the samples after protein precipitation, vigor-
ously vortexed for 30 s, and centrifuged for 5 min at
3,000×g, and the upper ethyl acetate layer was transferred
into Eppendorf vials. The extraction process was repeated
for the remaining water layer by adding 200 μLo fe t h y l
acetate, and the two resulting ethyl acetate fractions were
combined. The SPE/LLE eluents were dried under a gentle
flow of N2.
Derivatization reaction
The derivatization reagent PTAD was dissolved in acetoni-
trile [39] or ethyl acetate at different concentrations, and
samples were incubated at room temperature at various
incubation times [44]. Best results were obtained using
0.5 mg/mL PTAD in acetonitrile solution, and the reaction
was fully completed after 1 h at room temperature. In
subsequent experiments, the experimental conditions were
as follows: 50 μL of 0.5 mg/mL PTAD solution in
acetonitrile was added to the SPE/LLE eluents, vortexed
at room temperature for 1 h, and then transferred into
sample vials. Ten microliters of the mixture was injected
into the UHPLC-MS/MS system for analysis.
Fig. 1 Recovery of spiked components from plasma suing different
sample pretreatment methods (sequence: protein precipitation →
extraction → derivatization). LLE, 200 μL of plasma, dried and
extracted with 200 μL ethyl acetate and 100 μLH2O after protein
precipitation. SPE H2O, after protein precipitation, acetonitrile was
evaporated and water was added. SPE NaOH, SPE with 20 μL1M
NaOH added before protein precipitation. SPE NaOH HCl, SPE with
20 μL 1 M NaOH added before protein precipitation followed by
addition of HCl to pH 5 and SPE. Derivatization before SPE, plasma
sample were dried and derivatized with 50 μL of PTAD, addition of
800 μLo fH 2O before SPE
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Separations were performed using a Waters UPLC system
with Waters Acquity BEH C18 (1.7 μm), 2.1×50 mm
columns. Different mobile phase compositions were tested
(Fig. 3), and optimum results were obtained using a mobile
phase gradient consisting of 0.1% formic acid in water
(+5 mM methylamine) (A) and 0.1% formic acid in
methanol (B). The flow rate was set at 300 μL min
−1.
The gradient ran from 65% B to 98% B in 3.5 min and
remained at 98% B for 1 min before it was returned to 65%
B for equilibration. For MS/MS analysis, a QTRAP 4000
triple quadrupole-linear ion trap mass spectrometer with a
Turbolon-Spray interface (AB Sciex, Concord, Ontario,
Canada) was used. The instrument was operated in ESI-
positive ion multiple reaction monitoring (MRM) mode.
For all MRM experiments of non-derivatized and derivat-
ized vitamin D compounds, the (MH-H2O)
+ ions were used
as precursor ions, whereas (M + CH3NH3)
+ adduct ions
were used after CH3NH2 addition. MRM parameters were
optimized using direct infusion experiments of standard
compounds. The source parameters were optimized for
each analyte and internal standard using methanol/water/
formic acid (50:50:0.1, v/v/v). The ion spray voltage was set
to 5,500 V, source temperature to 550 °C, curtain gas to
10 psi, ion source gas 1 to 70 psi, and ion source gas 2 to
65 psi. The MRM sequence consisted of three individual
segments executed sequentially to monitor different transi-
tion pairs. The parameters for the MRM transitions are
summarized in Table 1.
Data analysis and assay performance
Analyst software version 1.4 (AB Sciex) was used for data
acquisition, statistical calculations, and quantitation. Linear
regression analysis using the least-squares method was used
to evaluate the calibration curve of each analyte as a
function of its concentration in plasma.
Assay precision and recovery rates
The intra- and inter-day coefficients of variation (CV),
reflecting assay precision, were calculated from measure-
ment of 10 samples extracted and analyzed in duplicate at
five time points per day. This was repeated on three
consecutive days. The recovery of the method was
examined by analyzing stable isotope-labeled standards
from plasma. A mixture of D6-25-OH D3, D6-25-OH D2,
D6-1,25-(OH)2 D3, and D6-1,25-(OH)2 D2 was prepared;
four different amounts were spiked into plasma and
incubated at room temperature for 10 to 120 min. Optimal
equilibration of the standard was found with 1 h incubation,
and this was used for the remaining data presented in this
paper. After incubation, the samples were pretreated and
extracted with SPE and LLE and derivatized as described
above. The recoveries were determined by comparing the
peak areas of these standards after protein precipitation and
SPE/LLE with peak areas from derivatized standards
solutions.
Cross-calibration of 25-OH D3 with other LC-MS/MS
methods and Diasorin immunoassays
The performance of the developed UHPLC-MS/MS
method was compared with other LC-MS/MS methods
registered with the vitamin D External Quality Assess-
ment Scheme (DEQAS, http://www.deqas.org)b yb l i n d
measurement of 12 samples in duplicate and comparison
of the results using regression and Bland and Altman
analysis. In addition, cross-calibration was performed with
Diasorin Liaison immunoassay (28 samples) and Diasorin
radio-immunoassay (RIA) (Diasorin, Still water, MN,
Table 1 MRM time segments, precursor/product ion transitions, and collision energies for the investigated vitamin D compounds
Segment PTAD derivative Precursor ion without additive Precursor ion with additive Collision energy Product ion
m/z
a m/z m/z
1 24,25(OH)2 D3 574 623 21 298
2 1,25-(OH)2 D3 574 623 22 314
2 1,25-(OH)2 D2 586 635 22 314
2 D6-1,25-(OH)2 D3 580 629 22 314
2 D6-1,25-(OH)2 D2 592 641 22 314
3 25-OH D3 558 607 25 298
3 25-OH D2 570 619 20 298
3 D6-25-OH D3 564 613 25 298
3 D6-25-OH D2 576 625 20 298
a(M + H–H2O)
+
782 S. Ding et al.USA) (14 samples) using plasma samples from subjects
included in earlier studies [42, 43]. The Diasorin Liaison
and RIA analysis were carried out as described earlier [42,
43], and statistical analyses was performed as described
above.
Results and discussion
Optimization of sample pretreatment and derivatization
procedures
Both SPE and LLE were evaluated for sample pretreatment
in this study. In these optimization experiments, deuterated
standards were spiked into plasma samples, and samples
were extracted using LLE or SPE. Particular attention in
these experiments was paid to the recovery of 1,25-(OH)2
D compounds because they are present in biological
samples at much lower concentration levels than the other
investigated vitamin D metabolites. The recoveries obtained
for the 1,25-(OH)2 D compounds using LLE and SPE were
similar, ranging from 71% to 86%. Ninety-six-well μelu-
tion SPE plates were also tested in this study, but the
obtained well-to-well reproducibilities were not satisfactory
(>10% relative standard deviations (RSD)), possibly due to
uneven elution rates across the plate and drying out of
individual sorbent wells. SPE was preferred over LLE in
subsequent experiments as it can be readily automated for
throughput enhancement. Further optimization steps were
performed for the SPE process as summarized in Fig. 1.
Addition of NaOH before protein precipitation was reported
to release analytes from vitamin D binding proteins [45]. In
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dissociation spectra of
1,25-(OH)2 D3 ((M + H-H2O)
+
at m/z 399, top spectrum) and
PTAD-derivatized 1,25-(OH)2
D3 (M + CH3NH3
+ at m/z 623,
bottom spectrum). The transition
m/z 623 → 314 was utilized
for MRM
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recovery of 25-OH D and 25-OH D2, but had no effect on
the recovery of low abundant 1,25-(OH)2 D. Therefore, to
simplify the protocol, SPE without NaOH addition was
used in subsequent experiments.
In the following experiments, different conditions for
the post-extraction derivatization reaction of vitamin D
compounds were evaluated. Because of the non-polar
nature of vitamin D derivatives [46], a derivatization
reaction was required in this study to enhance the
ionization efficiencies, thus allowing detection of the very
low abundant vitamin D metabolites. Specifically, PTAD
[41] was used here. This reagent has been previously
described, dissolved in either acetonitrile [39]o re t h y l
acetate [44]. Both solvents were also investigated here, at
different PTAD concentrations. It was found that a reagent
concentration of 0.5 mg/mL PTAD in acetonitrile
exhibited the highest signal-to-noise ratios in the mass
spectra. Different incubation times were also investigated,
showing completion of the reaction after 1 h at room
temperature. In addition, the derivatization reaction was
also investigated prior to SPE, but solid-phase extraction
of the derivatized vitamin D compounds resulted in very
low analyte recovery rates as compared with post-
extraction derivatization (Fig. 1), most likely due to the
increasedpolarityofthederivatizedanalytes.Forexample,for
1,25-(OH)2 D, a recovery rate of only 45% was obtained
for the derivatized compound versus 71% for the native
compound.
UHPLC-MS/MS conditions
In addition to the enhanced ionization efficiency, deriv-
a t i z a t i o nw i t hP T A Da l s os h i f t e dt h em/z ratios of the
precursor ions by ~200 Da to the region between m/z 600
and 650 Da, thus reducing interfering low m/z background
ions. Figure 2 shows the collision-induced dissociation
(CID) spectrum of PTAD-1,25-(OH)2 D3 and its proposed
fragmentation behavior in comparison with the under-
ivatized CID spectrum. Characteristically, the native
vitamin D compounds show very rich product ion spectra,
due to the availability of a large number of low-energy
fragmentation pathways. On the contrary, the product ion
spectrum of PTAD-derivatized 1,25-(OH)2 D3 exhibits
only one major fragment ion at m/z 314, which is beneficial
for sensitive MRM analysis. For MRM experiments of the
non-derivatized as well as the derivatized vitamin D
compounds, the (M + H–H2O)
+ ions were used as precursor
ions. However, as described in the “Experimental” section,
methylamine was subsequently added to the mobile
phase to further increase sensitivity, thus forming abundant
(M + CH3NH3)
+ adduct ions, with virtually identical MS/MS
behavior [41].
Different aqueous compositions of the mobile phase
were also tested in this study, and the results of these
experiments are summarized in Fig. 3. Aqueous mixtures
containing 0.1% formic acid and 5 mM methylamine
provided the highest signal intensities for vitamin D
compounds. Using the optimized UHPLC conditions, the
five vitamin D metabolites eluted within 4 min, as shown in
Fig. 4. Baseline separation was not achieved for all
compounds, but different MRM transition pairs could
readily be used to differentiate all targeted compounds.
Importantly, 24,25-(OH)2 D3, 1,25-(OH)2 D, and 25-OH D
w e r ef u l l ys e p a r a t e da n dm o n i t o r e di nd i f f e r e n tt i m e
windows of the MRM sequence, thus avoiding ion
suppression effects for low level compound such as 1,25-
(OH)2 D3 induced by compounds circulating at high
concentration levels, e.g., 25-OH D.
Two epimers, 6S and 6R, are produced by derivatization
with PTAD because the reagent reacts with the s-cis-diene
moiety from both the α- and β-sides; the ratio of 6S/6R is
approximately 4:1 [47]. As a result, two peaks may be
expected for each compound in the MRM ion chromato-
grams provided that the two epimers are fully separated
during chromatography. In this case, the major peak for the
6S-isomer can be used for integration and quantification. In
our study, the optimized flow rate of 300 μL min
−1 gave
separated epimers only for 24,25-(OH)2 D3 (Fig. 4); the
other compounds’ epimers eluted as one peak, which
further increased detection sensitivity.
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Fig. 3 MRM signal intensities obtained for different mobile phase
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(Solvent 1: A, 0.1% formic acid in H2O and B, 0.1% formic acid in
methanol. Solvent 2: A, 0.1% formic acid, 5 mM methylamine in H2O,
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ammonium formate in H2O and B, 0.1% formic acid in methanol.
Solvent 4:A ,1 0m M ammonium formate, 5 mM methylamine in H2O,
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The recovery rates of the vitamin D compounds were
examined by utilizing the stable isotope derivatives as
outlined in the “Experimental” section. The recoveries were
determined by comparing the peak areas of the MRM traces
of pure standard solutions with the areas of the recovered
stable isotope-labeled standards after incubation in plasma
and sample pretreatment as outlined above, in the concen-
tration range from 20 pg/μL to 2 ng/μL (Table 2). This
method showed satisfactory recovery ranging from 55% to
85%. Co-extracted and co-eluted matrix constituents could
potentially influence the ionization efficiencies of the
analyte and adversely affect reproducibility and accuracy
of the method, especially when external calibration curves
are used for quantitation. Therefore, deuterated internal
standards were utilized and were spiked to plasma samples
prior to the sample pretreatment, to counteract any target
ion suppression caused by the sample matrix. Furthermore,
blank plasma samples were processed and spiked with
deuterated standards at three concentration levels, 20, 200,
and 1,000 pg/μL. The peak area response was compared
with signals from injecting standard mixtures. The signal
differences for all the standards were <15%, suggesting
insignificant matrix effects.
Calibration curves were obtained from a series of
vitamin D metabolite reference standards over a wide
concentration range, using the corresponding stable isotope
compounds as internal standards. For 24,25-(OH)2 D3,
no deuterated standard was commercially available;
therefore, D6-1,25-(OH)2 D3 was used instead because
of its similar structure and physicochemical properties.
Calibration curves were constructed by plotting peak area
ratios of the MRM signals of the reference standard and
the internal standard against the concentration. An
example for a calibration curve is shown in Fig. 6.T h e
linear range and correlation coefficients obtained for the
regression analysis based on a minimum of six data points
a r es u m m a r i z e di nT a b l e3. The linear regression analysis
showed excellent linearity over the calibration range (r
2≥
0.999). The limit of quantitation (LOQ) was studied in
order to investigate the detection sensitivity of the
developed assay. In this study, the LOQ was defined as
the lowest concentration for which RSD values of 10% or
less were observed [48]. LOQ data (except for 24,25-
(OH)2 D3)a r es h o w ni nT a b l e3.T h eL O Q sf o rt h e
reference standards were ~20 pg/mL for 1,25-(OH)2 D3
and ~10 pg/mL for 1,25-(OH)2 D2,2 5 - O HD 3, and 25-
OH D2. The reproducibility of the proposed method was
evaluated by carrying out five replicate quantitative
determinations for each of the studied compounds spiked
in plasma, on the same day, and five replicates on three
consecutive days. Intra- and inter-day RSD values for the
quantitation of four vitamin D metabolites in human
plasma are summarized in Table 3. These numbers show
that excellent reproducibility can be obtained by this
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Fig. 4 UHPLC-MRM chromatograms for 5 vitamin D metabolites
Recovery 2 ng/μL 1 ng/μL 200 pg/μL 20 pg/μL
D6-1,25(OH)2 D3 70.6±1.4 59.9±2.3 63.6±12.3 55.6±5.5
D6-1,25(OH)2 D2 66.3±4.1 55.9±0.8 56.6±4.4 62.7±8.5
D6-25-OH D3 66.4±0.7 61.7±2.1 60.3±5.9 84.9±2.4
D6-25-OH D2 68.2±1.6 58.0±2.4 64.4±6.1 79.3±14.4
Table 2 Measured
recoveries and associated
precision (% recovery ± SD)
for deuterated compounds at
different fortification levels
in plasma
n=5
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ranged from 1.6% to 3.9% and 3.7% to 6.1%, respectively,
indicating little variation in the sample preparation and
UHPLC-MS/MS performance.
Method comparability and application
Significant inter-laboratory and inter-method variability
of the 25-OH D results exists [49–58], and there is
currently no method that is considered the gold standard
method for analyzing 25-OH D [22, 27]. The international
vitamin D Quality Assessment Scheme (DEQAS) mon-
itors the performance of laboratories measuring 25-OH D
using different analytical methods [50]a n da l l o w st h e
comparison between methods and between laboratories
using the same or similar methods. To assess the
comparability of the developed method with existing
methods, we performed regression and Bland–Altman
analysis on the 25-OH D concentration of 12 DEQAS
s a m p l e sa sm e a s u r e db yl a b o r a t o r i e sr e g i s t e r e dw i t h
D E Q A Su s i n gL C - M S( F i g .5a). A highly significant
linear association (r
2=0.9738; P<0.0001) was found,
and Bland–Altman analysis showed no concentration-
dependent and systematic differences between our and
other LC-MS methods (Fig. 5b). Also, a highly significant
linear association (r
2=0.9641; P<0.0001) was found
when comparing with DEQAS All Laboratory Trimmed
Mean (ALTM) values (Fig. 5a). Further, in-house cross-
calibration with two Diasorin methods was performed
using 42 plasma samples, 28 of which were analyzed with
a Liaison automated immunoassay platform and 14 with
the Diasorin RIA method (Fig. 6). Prior in-house cross-
correlation between these Diasorin methods showed a
high linear association and no systematic bias (unpub-
lished). UHPLC-MS/MS showed good correlation with
both Daisorin Liaison (r
2=0.8176) and RIA (r
2=0.9099;
Fig. 6). Bland–Altman analysis (Fig. 6) showed no
concentration-dependent and systematic differences be-
tween the Diasorin Liaison and our UHPLC-MS/MS
Table 3 Limits of quantitation (LOQ), linear dynamic range, and intra- and inter-day precision in the determination of vitamin D metabolites
from plasma
Component LOQ pg/mL (plasma) Linearity (pg/μL) r
2 Intra-day (%CV) Inter-day (%CV)
24,25-(OH)2 D3 n/a
a 0.1–300 0.9995 4.1 6.8
1,25-(OH)2 D3 20 0.2–50 0.9990 3.9 6.1
1,25-(OH)2 D2 10 0.1–50 0.9992 2.2 6.2
25-OH D3 10 2.5–300 0.9999 3.8 5.8
25-OH D2 10 2.5–300 0.9996 1.6 3.7
No LOD was given because of the lack of a commercial deuterated standard. 24,25(OH) D3 and 1,25(OH) D3 were similar, and the LOQ is
estimated to be similar to that of 1,25(OH) D3
a24,25-(OH)2 D3 was quantified using D6-25-OH D2 as internal standard
y = 0.8991x + 1.9645
r
2= 0.9738
y = 0.705x + 8.9059
r
2= 0.9641
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Fig. 5 Cross-calibration diagrams for 25-OH D: a in-house UHPLC-
MS/MS versus DEQAS LC-MS and DEQAS ALTM values for 12
DEQAS samples; b Bland–Altman plots (bottom)
786 S. Ding et al.method, whereas for the Diasorin RIA, there was a
significant negative linear association between the method
bias and concentration, indicating that the method
difference is higher at lower concentrations. In the future,
we will conduct further analyses to investigate the method
comparability for the present assay by using appropriate
certified reference materials (CRMs) compatible with the
diverse analytical methods for 25-OH D. The develop-
ment of CRMs, containing different levels of endogenous
vitamin D metabolites in human plasma, is currently
undertaken by the National Institute of Standards and
Technology (NIST), after the initial release of CRMs for
25-OH D (NIST SRM 972) containing horse serum and
exogenously spiked vitamin D metabolites [59]. Recent
research, however, has shown that the recovery of
exogenous vitamin D metabolites differs between immune
and chromatographic assays and that the use of non-
human serum may cause matrix effects [58, 60]a n di s
therefore inappropriate when comparing results derived
from different methods.
Finally, the circulating concentration of 1,25-(OH)2 D3 is
usually in the range 50–200 pmol/L (20–100 pg/mL) for
normal adults and usually at least 10× less for 1,25-
(OH)2 D2; values for 25-OH D in the population are
typically between 0.5 and 200 nmol/L (0.2–80 ng/mL),
and levels of 0.5–20 nmol/L (0.2–83 ng/mL) are seen for
24,25-OH D3 [7]. The limits of quantitation reported in
this study (Table 3) obtained from 200 μLo fp l a s m aa r e
sufficiently low to allow precise quantitative determina-
tion of the most important metabolites without analyte
enrichment during sample preparation. 1,25-(OH)2 Dm a y
be circulating at levels as low as 0.2 pg/mL [7]. Thus,
analyte enrichment would be required, which is easily
incorporated into the developed sample preparation pro-
tocol. Figure 7 shows typical MRM chromatograms for
some of the investigated vitamin D metabolites, illustrating
in particular the very low plasma concentrations seen for
1,25-(OH)2 D2.
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(the concentration levels are given in parentheses). a Vitamin D
metabolites 24,25-(OH)2 D3, 25-OH D3 and 25-OH D2; b low
abundant vitamin D metabolite 1,25-(OH)2 D3
R
2= 0.9099
RIA
y = 0.5306x + 27.9260
R
2= 0.8176
y = 0.6654x + 24.558
0
20
40
60
80
100
120
0 2 04 06 08 0 1 0 0 1 2 0
Liaison or RIA (nmoL/L)
U
P
L
C
/
M
S
/
M
S
 
(
n
m
o
L
/
L
) Liaison
RIA
y = -0.8377x + 66.28
R
2= 0.8047
y = -0.6371x + 42.95
R
2= 0.2821
-100
-80
-60
-40
-20
0
20
40
60
80
100
Average UPLC-MS/MS and Liaison or RIA
%
 
U
P
L
C
-
M
S
/
M
S
-
L
i
a
i
s
o
n
 
o
r
 
R
I
A
Liaison
30 40 50 60 70 80 90
Fig. 6 Regression analysis of 25-OH D plasma concentrations in 42 subjects measured by in-house UHPLC-MS/MS and Diasorin Liaison and
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Quantitative determination of vitamin D metabolites in plasma 787Conclusions
In this report, we describe the development of a UHPLC-
MS/MS assay for simultaneous quantification of five
important vitamin D metabolites, namely, 25-OH D3,2 5 -
OH D2,2 4 , 2 5 - ( O H ) 2 D3,1 , 2 5 - ( O H ) 2 D3, and 1,25-(OH)2 D2
in human plasma. This method utilizes SPE of plasma
samples, followed by PTAD derivatization and methylamine
addition to enhance detection sensitivity. MRM analysis was
carried out on a triple quadrupole mass spectrometer. The
limits of quantitation for all investigated compounds were
between 10 and 20 pg/mL, with linear dynamic ranges of up
to three orders of magnitude. Precision values in human
plasma demonstrated excellent performance, ranging from
1.6% to 3.9% and 3.7% t 6.1% for intra- and inter-day
measurements, respectively. Finally, the method showed high
correlation with established techniques for the measurement
of 25-OH D.
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